APO Research
Talk to an analyst

APO RESEARCH · REPORT

IgA Nephropathy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IgA Nephropathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025182 pages

Choose your research edition.

Industry ResearchIgA Nephropathy Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal IgA Nephropathy Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal IgA Nephropathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IgA Nephropathy Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal IgA Nephropathy Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global IgA Nephropathy Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IgA Nephropathy Drugs include Calliditas Therapeutics, Chinook Therapeutics, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, Otsuka Pharmaceutical and Novartis International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IgA Nephropathy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IgA Nephropathy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IgA Nephropathy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IgA Nephropathy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

IgA Nephropathy Drugs Segment by Company

Calliditas Therapeutics

Chinook Therapeutics

Omeros Corporation

Travere Therapeutics

Vera Therapeutics

Otsuka Pharmaceutical

Novartis International

IgA Nephropathy Drugs Segment by Type

Phase I

Phase II

Phase III

IgA Nephropathy Drugs Segment by Application

Clinical Treatment

Drug Experiment

IgA Nephropathy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IgA Nephropathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IgA Nephropathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IgA Nephropathy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IgA Nephropathy Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IgA Nephropathy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of IgA Nephropathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of IgA Nephropathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. IgA Nephropathy Drugs Industry Trends Table 2. IgA Nephropathy Drugs Industry Drivers Table 3. IgA Nephropathy Drugs Industry Opportunities and Challenges Table 4. IgA Nephropathy Drugs Industry Restraints Table 5. Global IgA Nephropathy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global IgA Nephropathy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global IgA Nephropathy Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global IgA Nephropathy Drugs Sales Market Share by Manufacturers Table 9. Global IgA Nephropathy Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global IgA Nephropathy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global IgA Nephropathy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global IgA Nephropathy Drugs Manufacturers, Product Type & Application Table 13. Global IgA Nephropathy Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global IgA Nephropathy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Phase I Table 17. Major Manufacturers of Phase II Table 18. Major Manufacturers of Phase III Table 19. Global IgA Nephropathy Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global IgA Nephropathy Drugs Sales by Type (2021-2026) & (K Units) Table 21. Global IgA Nephropathy Drugs Sales by Type (2027-2032) & (K Units) Table 22. Global IgA Nephropathy Drugs Sales Market Share by Type (2021-2026) Table 23. Global IgA Nephropathy Drugs Sales Market Share by Type (2027-2032) Table 24. Global IgA Nephropathy Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global IgA Nephropathy Drugs Revenue by Type (2021-2026) & (K Units) Table 26. Global IgA Nephropathy Drugs Revenue by Type (2027-2032) & (K Units) Table 27. Global IgA Nephropathy Drugs Revenue Market Share by Type (2021-2026) Table 28. Global IgA Nephropathy Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Clinical Treatment Table 30. Major Manufacturers of Drug Experiment Table 31. Global IgA Nephropathy Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global IgA Nephropathy Drugs Sales by Application (2021-2026) & (K Units) Table 33. Global IgA Nephropathy Drugs Sales by Application (2027-2032) & (K Units) Table 34. Global IgA Nephropathy Drugs Sales Market Share by Application (2021-2026) Table 35. Global IgA Nephropathy Drugs Sales Market Share by Application (2027-2032) Table 36. Global IgA Nephropathy Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global IgA Nephropathy Drugs Revenue by Application (2021-2026) & (K Units) Table 38. Global IgA Nephropathy Drugs Revenue by Application (2027-2032) & (K Units) Table 39. Global IgA Nephropathy Drugs Revenue Market Share by Application (2021-2026) Table 40. Global IgA Nephropathy Drugs Revenue Market Share by Application (2027-2032) Table 41. Global IgA Nephropathy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global IgA Nephropathy Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global IgA Nephropathy Drugs Sales Market Share by Region (2021-2026) Table 44. Global IgA Nephropathy Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global IgA Nephropathy Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 48. North America IgA Nephropathy Drugs Sales by Country (2027-2032) & (K Units) Table 49. Europe IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 51. Europe IgA Nephropathy Drugs Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific IgA Nephropathy Drugs Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa IgA Nephropathy Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global IgA Nephropathy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global IgA Nephropathy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global IgA Nephropathy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global IgA Nephropathy Drugs Revenue Market Share by Region (2021-2026) Table 62. Global IgA Nephropathy Drugs Revenue Market Share by Region (2027-2032) Table 63. Calliditas Therapeutics Company Information Table 64. Calliditas Therapeutics Business Overview Table 65. Calliditas Therapeutics IgA Nephropathy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Calliditas Therapeutics IgA Nephropathy Drugs Product Portfolio Table 67. Calliditas Therapeutics Recent Development Table 68. Chinook Therapeutics Company Information Table 69. Chinook Therapeutics Business Overview Table 70. Chinook Therapeutics IgA Nephropathy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Chinook Therapeutics IgA Nephropathy Drugs Product Portfolio Table 72. Chinook Therapeutics Recent Development Table 73. Omeros Corporation Company Information Table 74. Omeros Corporation Business Overview Table 75. Omeros Corporation IgA Nephropathy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Omeros Corporation IgA Nephropathy Drugs Product Portfolio Table 77. Omeros Corporation Recent Development Table 78. Travere Therapeutics Company Information Table 79. Travere Therapeutics Business Overview Table 80. Travere Therapeutics IgA Nephropathy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Travere Therapeutics IgA Nephropathy Drugs Product Portfolio Table 82. Travere Therapeutics Recent Development Table 83. Vera Therapeutics Company Information Table 84. Vera Therapeutics Business Overview Table 85. Vera Therapeutics IgA Nephropathy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Vera Therapeutics IgA Nephropathy Drugs Product Portfolio Table 87. Vera Therapeutics Recent Development Table 88. Otsuka Pharmaceutical Company Information Table 89. Otsuka Pharmaceutical Business Overview Table 90. Otsuka Pharmaceutical IgA Nephropathy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Otsuka Pharmaceutical IgA Nephropathy Drugs Product Portfolio Table 92. Otsuka Pharmaceutical Recent Development Table 93. Novartis International Company Information Table 94. Novartis International Business Overview Table 95. Novartis International IgA Nephropathy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Novartis International IgA Nephropathy Drugs Product Portfolio Table 97. Novartis International Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. IgA Nephropathy Drugs Distributors List Table 101. IgA Nephropathy Drugs Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. IgA Nephropathy Drugs Product Image Figure 2. Global IgA Nephropathy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IgA Nephropathy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global IgA Nephropathy Drugs Sales (2021-2032) & (K Units) Figure 5. Global IgA Nephropathy Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 IgA Nephropathy Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Phase I Image Figure 9. Phase II Image Figure 10. Phase III Image Figure 11. Global IgA Nephropathy Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global IgA Nephropathy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global IgA Nephropathy Drugs Sales Market Share by Type (2021-2032) Figure 14. Global IgA Nephropathy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global IgA Nephropathy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global IgA Nephropathy Drugs Revenue Market Share by Type (2021-2032) Figure 17. Clinical Treatment Image Figure 18. Drug Experiment Image Figure 19. Global IgA Nephropathy Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global IgA Nephropathy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global IgA Nephropathy Drugs Sales Market Share by Application (2021-2032) Figure 22. Global IgA Nephropathy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global IgA Nephropathy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global IgA Nephropathy Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America IgA Nephropathy Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe IgA Nephropathy Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific IgA Nephropathy Drugs Sales Market Share by Country (2021-2032) Figure 39. China IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa IgA Nephropathy Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile IgA Nephropathy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global IgA Nephropathy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global IgA Nephropathy Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America IgA Nephropathy Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe IgA Nephropathy Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific IgA Nephropathy Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa IgA Nephropathy Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. IgA Nephropathy Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. IgA Nephropathy Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Phase I
  • Phase II
  • Phase III
Applications
  • Clinical Treatment
  • Drug Experiment
Companies covered
  • Calliditas Therapeutics
  • Chinook Therapeutics
  • Omeros Corporation
  • Travere Therapeutics
  • Vera Therapeutics
  • Otsuka Pharmaceutical
  • Novartis International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IgA Nephropathy Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IgA Nephropathy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global IgA Nephropathy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global IgA Nephropathy Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global IgA Nephropathy Drugs Market Dynamics
  1. 2.1 IgA Nephropathy Drugs Industry Trends
  2. 2.2 IgA Nephropathy Drugs Industry Drivers
  3. 2.3 IgA Nephropathy Drugs Industry Opportunities and Challenges
  4. 2.4 IgA Nephropathy Drugs Industry Restraints
3 IgA Nephropathy Drugs Market by Manufacturers
  1. 3.1 Global IgA Nephropathy Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global IgA Nephropathy Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global IgA Nephropathy Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global IgA Nephropathy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IgA Nephropathy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global IgA Nephropathy Drugs Manufacturers, Product Type & Application
  7. 3.7 Global IgA Nephropathy Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IgA Nephropathy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IgA Nephropathy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IgA Nephropathy Drugs Tier 1, Tier 2, and Tier 3
4 IgA Nephropathy Drugs Market by Type
  1. 4.1 IgA Nephropathy Drugs Type Introduction
  2. 4.1.1 Phase I
  3. 4.1.2 Phase II
  4. 4.1.3 Phase III
  5. 4.2 Global IgA Nephropathy Drugs Sales by Type
  6. 4.2.1 Global IgA Nephropathy Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global IgA Nephropathy Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global IgA Nephropathy Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global IgA Nephropathy Drugs Revenue by Type
  10. 4.3.1 Global IgA Nephropathy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global IgA Nephropathy Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global IgA Nephropathy Drugs Revenue Market Share by Type (2021-2032)
5 IgA Nephropathy Drugs Market by Application
  1. 5.1 IgA Nephropathy Drugs Application Introduction
  2. 5.1.1 Clinical Treatment
  3. 5.1.2 Drug Experiment
  4. 5.2 Global IgA Nephropathy Drugs Sales by Application
  5. 5.2.1 Global IgA Nephropathy Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global IgA Nephropathy Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global IgA Nephropathy Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global IgA Nephropathy Drugs Revenue by Application
  9. 5.3.1 Global IgA Nephropathy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global IgA Nephropathy Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global IgA Nephropathy Drugs Revenue Market Share by Application (2021-2032)
6 Global IgA Nephropathy Drugs Sales by Region
  1. 6.1 Global IgA Nephropathy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IgA Nephropathy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global IgA Nephropathy Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global IgA Nephropathy Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America IgA Nephropathy Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe IgA Nephropathy Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific IgA Nephropathy Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa IgA Nephropathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa IgA Nephropathy Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global IgA Nephropathy Drugs Revenue by Region
  1. 7.1 Global IgA Nephropathy Drugs Revenue by Region
  2. 7.1.1 Global IgA Nephropathy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global IgA Nephropathy Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global IgA Nephropathy Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global IgA Nephropathy Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America IgA Nephropathy Drugs Revenue (2021-2032)
  8. 7.2.2 North America IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe IgA Nephropathy Drugs Revenue (2021-2032)
  11. 7.3.2 Europe IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific IgA Nephropathy Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa IgA Nephropathy Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa IgA Nephropathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Calliditas Therapeutics
  2. 8.1.1 Calliditas Therapeutics Company Information
  3. 8.1.2 Calliditas Therapeutics Business Overview
  4. 8.1.3 Calliditas Therapeutics IgA Nephropathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Calliditas Therapeutics IgA Nephropathy Drugs Product Portfolio
  6. 8.1.5 Calliditas Therapeutics Recent Developments
  7. 8.2 Chinook Therapeutics
  8. 8.2.1 Chinook Therapeutics Company Information
  9. 8.2.2 Chinook Therapeutics Business Overview
  10. 8.2.3 Chinook Therapeutics IgA Nephropathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Chinook Therapeutics IgA Nephropathy Drugs Product Portfolio
  12. 8.2.5 Chinook Therapeutics Recent Developments
  13. 8.3 Omeros Corporation
  14. 8.3.1 Omeros Corporation Company Information
  15. 8.3.2 Omeros Corporation Business Overview
  16. 8.3.3 Omeros Corporation IgA Nephropathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Omeros Corporation IgA Nephropathy Drugs Product Portfolio
  18. 8.3.5 Omeros Corporation Recent Developments
  19. 8.4 Travere Therapeutics
  20. 8.4.1 Travere Therapeutics Company Information
  21. 8.4.2 Travere Therapeutics Business Overview
  22. 8.4.3 Travere Therapeutics IgA Nephropathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Travere Therapeutics IgA Nephropathy Drugs Product Portfolio
  24. 8.4.5 Travere Therapeutics Recent Developments
  25. 8.5 Vera Therapeutics
  26. 8.5.1 Vera Therapeutics Company Information
  27. 8.5.2 Vera Therapeutics Business Overview
  28. 8.5.3 Vera Therapeutics IgA Nephropathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Vera Therapeutics IgA Nephropathy Drugs Product Portfolio
  30. 8.5.5 Vera Therapeutics Recent Developments
  31. 8.6 Otsuka Pharmaceutical
  32. 8.6.1 Otsuka Pharmaceutical Company Information
  33. 8.6.2 Otsuka Pharmaceutical Business Overview
  34. 8.6.3 Otsuka Pharmaceutical IgA Nephropathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Otsuka Pharmaceutical IgA Nephropathy Drugs Product Portfolio
  36. 8.6.5 Otsuka Pharmaceutical Recent Developments
  37. 8.7 Novartis International
  38. 8.7.1 Novartis International Company Information
  39. 8.7.2 Novartis International Business Overview
  40. 8.7.3 Novartis International IgA Nephropathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis International IgA Nephropathy Drugs Product Portfolio
  42. 8.7.5 Novartis International Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IgA Nephropathy Drugs Value Chain Analysis
  2. 9.1.1 IgA Nephropathy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IgA Nephropathy Drugs Production Mode & Process
  6. 9.2 IgA Nephropathy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IgA Nephropathy Drugs Distributors
  9. 9.2.3 IgA Nephropathy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst